Abstract
Circumsporozoite protein (CSP) variants of P. vivax, besides having variations in the protein repetitive portion, can differ from each other in aspects such as geographical distribution, intensity of transmission, vectorial competence and immune response. Such aspects must be considered to P. vivax vaccine development. Therefore, we evaluated the immunogenicity of novel recombinant proteins corresponding to each of the three P. vivax allelic variants (VK210, VK247 and P. vivax-like) and of the C-terminal region (shared by all PvCSP variants) in naturally malaria-exposed populations of Brazilian Amazon. Our results demonstrated that PvCSP-VK210 was the major target of humoral immune response in studied population, presenting higher frequency and magnitude of IgG response. The IgG subclass profile showed a prevalence of cytophilic antibodies (IgG1 and IgG3), that seem to have an essential role in protective immune response. Differently of PvCSP allelic variants, antibodies elicited against C-terminal region of protein did not correlate with epidemiological parameters, bringing additional evidence that humoral response against this protein region is not essential to protective immunity. Taken together, these findings increase the knowledge on serological response to distinct PvCSP allelic variants and may contribute to the development of a global and effective P. vivax vaccine.
Highlights
Circumsporozoite protein (CSP) variants of P. vivax, besides having variations in the protein repetitive portion, can differ from each other in aspects such as geographical distribution, intensity of transmission, vectorial competence and immune response
Previous works have proposed that CSP variants of P. vivax, besides having variations in the repetitive portion of the protein, can differ from each other in aspects such as geographical distribution, intensity of transmission, vectorial competence, immune response, response to treatment and drug resistance[23,27,28,29]
We evaluated and characterized the humoral IgG response to the P. vivax CSP (PvCSP) variant repeats (VK210, VK247 and P. vivax-like) and the C-terminal region, in a population consisting of 299 individuals naturally exposed to P. vivax malaria, living in Acre, a state of the malaria endemic Brazilian Amazon
Summary
Circumsporozoite protein (CSP) variants of P. vivax, besides having variations in the protein repetitive portion, can differ from each other in aspects such as geographical distribution, intensity of transmission, vectorial competence and immune response Such aspects must be considered to P. vivax vaccine development. Of PvCSP allelic variants, antibodies elicited against C-terminal region of protein did not correlate with epidemiological parameters, bringing additional evidence that humoral response against this protein region is not essential to protective immunity. Taken together, these findings increase the knowledge on serological response to distinct PvCSP allelic variants and may contribute to the development of a global and effective P. vivax vaccine. Some particularities of P. vivax, such as the increasing numbers of reports of severe vivax m alaria[12,13,14,15] and the appearance of strains resistant to t reatment[16,17,18], highlight the importance of the development of a specific vaccine against P. vivax
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
